Mouse anti Human CD33Catalog number: 0331
Identification of human Monocytes (bright) and Granulocytes (dim) expressing the 67kDa M.W. surface antigen. CD33 is also found on CFU-mix, CFU-GM, CFU-Meg, a portion of BFU-E, myeloblasts, promyelocytes, myelocytes, metamyelocytes but not early precursors
Immunogen: CD33=Derived from the hybridization of mouse Sp2/0 myeloma cells with spleen cells from BALB/c mice immunized with FMY9S5 cells containing the CD33 gene.
Product Form: Unconjugated
Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide
Purification Method: Protein A/G Chromatography
Concentration: See vial for concentration
PBMC: Add10 µl of MAB/10^6 PBMC in 100 µl PBS. Mix gently and incubate for 15 minutes at 2º to 8ºC. Wash twice with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. WHOLE BLOOD: Add10 µl of MAB/100 µl of whole blood. Mix gently and incubate for 15 minutes at room temperature 20ºC. Lyse the whole blood. Wash once with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. See instrument manufacturer’s instructions for Lysed Whole Blood and Immunofluorescence analysis with a flow cytometer or microscope.
Functional Analysis: Flow Cytometry Staining
Product should be stored at -20ºC. Aliquot to avoid freeze/thaw cycles
Product Stability: See expiration date on vial
Shipping Conditions: Room Temperature
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.
1. Comparsion of outcome, clinical, laboratory, and immunological features in 164 children and adults with T-ALL. Garand, R., Vannier, J.P., Bene, M.C., Faure, G., Favre, M., Bernard, A,. Leukemia,1990 No;4(11):739-44. 2. Immunologic Classification of Leukemia and Lymphoma. Foon, K.A., Todd, III,R.F. (1986)(1986) Blood ,68, 1 3. Surface marker expression in acute myeloid leukaemia at first relapse. Thomas X; Campos L; Archimbaud E; Shi ZH; TreilleRitouet D; Anglaret B; Fiere D Br J Haematol 1992 May;81(1):40-4 4. Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Robertson MJ; Soiffer RJ; Freedman AS; Rabinowe SL; Anderson KC; Ervin TJ; Murray C; Dear K; Griffin JD; Nadler LM; et al Blood 1992 May 1;79(9):2229-36 5. Expression of myeloid differentiation antigens in acute nonlymphocytic leukemia: increased concentration of CD33 antigen predicts poor outcome--a report from the Childrens Cancer Study Group. Dinndorf PA; Buckley JD; Nesbit ME; Lampkin BC; Piomelli S; Feig SA; Kersey JH; Hammond GD; Bernstein ID Med Pediatr Oncol 1992;20(3):192-200 6. Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia. Bernstein ID; Singer JW; Smith FO; Andrews RG; Flowers DA; Petersens J; Steinmann L; Najfeld V; Savage D; Fruchtman S; et al Blood 1992 Apr 1;79(7):1811-6 7. The role of an anti-myeloperoxidase antibody in the diagnosis and classification of acute leukaemia: a comparison with light and electron microscopy cytochemistry. Buccheri V; Shetty V; Yoshida N; Morilla R; Matutes E; Catovsky D Br J Haematol 1992 Jan;80(1):62-8
Database Name: UniProt
Accession Number: P20138
Safety Datasheet(s) for this product: